Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
Adolescent
Adult
Aminoquinolines
/ administration & dosage
Antimalarials
/ administration & dosage
Chloroquine
/ administration & dosage
Cytochrome P-450 CYP2D6
/ metabolism
Disease-Free Survival
Double-Blind Method
Drug Therapy, Combination
Female
Glucosephosphate Dehydrogenase
/ metabolism
Hemoglobins
/ analysis
Humans
Intention to Treat Analysis
Kaplan-Meier Estimate
Logistic Models
Malaria, Vivax
/ drug therapy
Male
Parasitemia
/ drug therapy
Plasmodium vivax
/ isolation & purification
Primaquine
/ administration & dosage
Secondary Prevention
/ methods
Journal
The New England journal of medicine
ISSN: 1533-4406
Titre abrégé: N Engl J Med
Pays: United States
ID NLM: 0255562
Informations de publication
Date de publication:
17 01 2019
17 01 2019
Historique:
entrez:
17
1
2019
pubmed:
17
1
2019
medline:
31
1
2019
Statut:
ppublish
Résumé
Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed "radical cure"). Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P. vivax. This multicenter, double-blind, double-dummy, parallel group, randomized, placebo-controlled trial was conducted in Ethiopia, Peru, Brazil, Cambodia, Thailand, and the Philippines. We enrolled 522 patients with microscopically confirmed P. vivax infection (>100 to <100,000 parasites per microliter) and normal glucose-6-phosphate dehydrogenase (G6PD) activity (with normal activity defined as ≥70% of the median value determined at each trial site among 36 healthy male volunteers who were otherwise not involved in the trial). All patients received a 3-day course of chloroquine (total dose of 1500 mg). In addition, patients were assigned to receive a single 300-mg dose of tafenoquine on day 1 or 2 (260 patients), placebo (133 patients), or a 15-mg dose of primaquine once daily for 14 days (129 patients). The primary outcome was the Kaplan-Meier estimated percentage of patients who were free from recurrence at 6 months, defined as P. vivax clearance without recurrent parasitemia. In the intention-to-treat population, the percentage of patients who were free from recurrence at 6 months was 62.4% in the tafenoquine group (95% confidence interval [CI], 54.9 to 69.0), 27.7% in the placebo group (95% CI, 19.6 to 36.6), and 69.6% in the primaquine group (95% CI, 60.2 to 77.1). The hazard ratio for the risk of recurrence was 0.30 (95% CI, 0.22 to 0.40) with tafenoquine as compared with placebo (P<0.001) and 0.26 (95% CI, 0.18 to 0.39) with primaquine as compared with placebo (P<0.001). Tafenoquine was associated with asymptomatic declines in hemoglobin levels, which resolved without intervention. Single-dose tafenoquine resulted in a significantly lower risk of P. vivax recurrence than placebo in patients with phenotypically normal G6PD activity. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; DETECTIVE ClinicalTrials.gov number, NCT01376167 .).
Sections du résumé
BACKGROUND
Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed "radical cure"). Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P. vivax.
METHODS
This multicenter, double-blind, double-dummy, parallel group, randomized, placebo-controlled trial was conducted in Ethiopia, Peru, Brazil, Cambodia, Thailand, and the Philippines. We enrolled 522 patients with microscopically confirmed P. vivax infection (>100 to <100,000 parasites per microliter) and normal glucose-6-phosphate dehydrogenase (G6PD) activity (with normal activity defined as ≥70% of the median value determined at each trial site among 36 healthy male volunteers who were otherwise not involved in the trial). All patients received a 3-day course of chloroquine (total dose of 1500 mg). In addition, patients were assigned to receive a single 300-mg dose of tafenoquine on day 1 or 2 (260 patients), placebo (133 patients), or a 15-mg dose of primaquine once daily for 14 days (129 patients). The primary outcome was the Kaplan-Meier estimated percentage of patients who were free from recurrence at 6 months, defined as P. vivax clearance without recurrent parasitemia.
RESULTS
In the intention-to-treat population, the percentage of patients who were free from recurrence at 6 months was 62.4% in the tafenoquine group (95% confidence interval [CI], 54.9 to 69.0), 27.7% in the placebo group (95% CI, 19.6 to 36.6), and 69.6% in the primaquine group (95% CI, 60.2 to 77.1). The hazard ratio for the risk of recurrence was 0.30 (95% CI, 0.22 to 0.40) with tafenoquine as compared with placebo (P<0.001) and 0.26 (95% CI, 0.18 to 0.39) with primaquine as compared with placebo (P<0.001). Tafenoquine was associated with asymptomatic declines in hemoglobin levels, which resolved without intervention.
CONCLUSIONS
Single-dose tafenoquine resulted in a significantly lower risk of P. vivax recurrence than placebo in patients with phenotypically normal G6PD activity. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; DETECTIVE ClinicalTrials.gov number, NCT01376167 .).
Identifiants
pubmed: 30650322
doi: 10.1056/NEJMoa1710775
pmc: PMC6657226
doi:
Substances chimiques
Aminoquinolines
0
Antimalarials
0
Hemoglobins
0
tafenoquine
262P8GS9L9
Chloroquine
886U3H6UFF
G6PD protein, human
EC 1.1.1.49
Glucosephosphate Dehydrogenase
EC 1.1.1.49
Cytochrome P-450 CYP2D6
EC 1.14.14.1
Primaquine
MVR3634GX1
Banques de données
ClinicalTrials.gov
['NCT01376167']
Types de publication
Clinical Trial, Phase II
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
215-228Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Références
Blood Cells Mol Dis. 2005 Mar-Apr;34(2):191-6
pubmed: 15727905
Curr Infect Dis Rep. 2007 Jan;9(1):39-46
pubmed: 17254503
Clin Biochem. 2007 Jun;40(9-10):699-704
pubmed: 17499234
Clin Pharmacol Ther. 2008 Feb;83(2):234-42
pubmed: 17971818
J Infect Dis. 2009 Apr 1;199(7):1074-80
pubmed: 19275476
Malar J. 2010 Nov 01;9:308
pubmed: 21040545
Biomed Chromatogr. 2011 Sep;25(9):1010-7
pubmed: 21058417
Am J Trop Med Hyg. 2011 Jan;84(1):137-40
pubmed: 21212216
Malar J. 2011 Dec 13;10:355
pubmed: 22165853
PLoS Med. 2012;9(11):e1001339
pubmed: 23152723
Adv Parasitol. 2012;80:113-50
pubmed: 23199487
Malar J. 2013 Jun 20;12:212
pubmed: 23782898
N Engl J Med. 2013 Oct 3;369(14):1381-2
pubmed: 24088113
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17486-91
pubmed: 24101478
Cochrane Database Syst Rev. 2013 Oct 26;(10):CD004389
pubmed: 24163057
Lancet. 2014 Mar 22;383(9922):1049-58
pubmed: 24360369
Malar J. 2014 Aug 15;13:321
pubmed: 25127886
Mem Inst Oswaldo Cruz. 2014 Aug;109(5):534-9
pubmed: 25184999
Lancet Infect Dis. 2014 Oct;14(10):982-91
pubmed: 25213732
PLoS One. 2014 Oct 20;9(10):e110691
pubmed: 25329392
Malar J. 2014 Dec 12;13:488
pubmed: 25495607
J Infect Dis. 2016 Mar 1;213(5):794-9
pubmed: 26500351
Malar J. 2016 Feb 18;15:97
pubmed: 26888075
Acta Trop. 2016 Aug;160:35-8
pubmed: 27109040
Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):15-34
pubmed: 27402513
PLoS One. 2016 Jul 28;11(7):e0160172
pubmed: 27467145
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7321-7332
pubmed: 27697758
Malar J. 2017 Apr 5;16(1):141
pubmed: 28381261
PLoS Med. 2017 May 16;14(5):e1002299
pubmed: 28510573
Am J Trop Med Hyg. 2017 Sep;97(3):702-711
pubmed: 28749773
PLoS Med. 2017 Aug 29;14(8):e1002379
pubmed: 28850568
N Engl J Med. 2019 Jan 17;380(3):229-241
pubmed: 30650326
J Lab Clin Med. 1981 Jun;97(6):750-9
pubmed: 7229509